Cullinan Therapeutics, Inc. (NasdaqGS: CGEM)
Health Care · Biotechnology · US
$22.75
-0.87% today · +200.4% 1Y
Cullinan Therapeutics, Inc. (NasdaqGS: CGEM) operates in the Biotechnology industry within the Health Care sector. The company is valued at $1.48B and employs 109 people.
Over the last twelve months the share price has gained 200.4%, trading between 5.68 and 22.54.
Tweenvest scores Cullinan Therapeutics, Inc. across four factors: quality 31/100. Its strongest factor is quality.
CGEM price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.48B
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -3.47
- Dividend yield
- —
- Beta (5Y)
- -0.02
- 52-week high
- $22.54
- 52-week low
- $5.68
- Avg volume (3M)
- —
- Shares outstanding
- 64.35M
- Employees
- 109
- Next earnings
- —
About Cullinan Therapeutics, Inc.
Cullinan Therapeutics, Inc. operates as a biopharmaceutical firm actively advancing its therapeutic candidates through clinical trials. This company is focused on developing innovative treatments primarily for cancer, including those that leverage the immune system (immuno-oncology). Its current roster of investigational drugs comprises CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. Patrick A. Baeuerle founded the organization on September 15, 2016, and it is presently headquartered in Cambridge, Massachusetts.
- ISIN
- US2300311063
- Founded
- 2016
- Listed since
- Jan 8, 2021
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $266.00 | +0.08% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $442.45 | +0.05% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.10 | -0.45% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $551.33 | -0.27% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $832.63 | -0.11% |
| argenx SEENXTBR: ARGX | $64.17B | €909.60 | +3.46% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $153.70 | -3.23% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.